Pentwater Capital Management LP Takes $1.40 Million Position in Karuna Therapeutics (NASDAQ:KRTX)

Pentwater Capital Management LP acquired a new position in Karuna Therapeutics (NASDAQ:KRTX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 70,000 shares of the company’s stock, valued at approximately $1,401,000. Pentwater Capital Management LP owned about 0.30% of Karuna Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new stake in Karuna Therapeutics during the 2nd quarter worth approximately $1,008,000. Vanguard Group Inc. purchased a new position in shares of Karuna Therapeutics in the 2nd quarter valued at $1,294,000. Rock Springs Capital Management LP purchased a new position in Karuna Therapeutics during the 2nd quarter worth $8,278,000. Laurion Capital Management LP purchased a new position in Karuna Therapeutics during the 2nd quarter worth $1,001,000. Finally, Vivo Capital LLC purchased a new position in Karuna Therapeutics during the 2nd quarter worth $6,507,000. Hedge funds and other institutional investors own 36.98% of the company’s stock.

In other news, CEO Steven M. Paul acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average price of $23.04 per share, for a total transaction of $230,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James Healy purchased 700,000 shares of the stock in a transaction on Tuesday, July 2nd. The shares were bought at an average price of $16.00 per share, for a total transaction of $11,200,000.00. The disclosure for this purchase can be found here. Insiders have acquired 910,000 shares of company stock valued at $14,630,400 over the last ninety days.



Shares of Karuna Therapeutics stock traded down $0.01 during trading on Friday, hitting $16.90. 2,166 shares of the stock were exchanged, compared to its average volume of 91,254. The company has a fifty day moving average of $19.47. Karuna Therapeutics has a 12 month low of $15.31 and a 12 month high of $29.00.

Karuna Therapeutics (NASDAQ:KRTX) last announced its earnings results on Thursday, August 8th. The company reported ($146.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($144.83). As a group, research analysts expect that Karuna Therapeutics will post -2.48 earnings per share for the current year.

Several research firms have recently commented on KRTX. Wells Fargo & Co assumed coverage on shares of Karuna Therapeutics in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price for the company. Citigroup assumed coverage on shares of Karuna Therapeutics in a report on Tuesday, July 23rd. They set a “buy” rating and a $28.00 price target for the company. Goldman Sachs Group assumed coverage on shares of Karuna Therapeutics in a report on Tuesday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Karuna Therapeutics in a report on Friday, August 9th.

Karuna Therapeutics Company Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain.

Featured Story: Arbitrage

Want to see what other hedge funds are holding KRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karuna Therapeutics (NASDAQ:KRTX).

Institutional Ownership by Quarter for Karuna Therapeutics (NASDAQ:KRTX)

Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.